Literature DB >> 26962963

Increased von Willebrand factor, P-selectin and fibrin content in occlusive thrombus resistant to lytic therapy.

Antonia Sambola1, Bruno García Del Blanco, Marisol Ruiz-Meana, Jaume Francisco, José A Barrabés, Jaume Figueras, Jordi Bañeras, Imanol Otaegui, Angeles Rojas, Úrsula Vilardosa, Joan Montaner, David García-Dorado.   

Abstract

Therapeutic fibrinolysis is ineffective in 40 % of ST-segment elevation acute myocardial infarction (STEMI) patients, but understanding of the mechanisms is incomplete. It was our aim to compare the composition of coronary thrombus in lysis-resistant STEMI patients with that of lysis-sensitive patients. Intracoronary thrombi (n=64) were obtained by aspiration in consecutive STEMI patients. Of them, 20 had received fibrinolysis and underwent rescue percutaneous coronary intervention (r-PCI, lysis-resistant patients) and 44 underwent primary PCI (p-PCI). Lysis-sensitivity was determined in vitro by clot permeability measurements and turbidimetric lysis in plasma of 44 patients undergoing p-PCI and 20 healthy donors. Clot-lysis sensitivity was defined as a clot-lysis time not greater than 1 SD over the mean of healthy donors. Coronary thrombus composition in 20 lysis-resistant and in 20 lysis-sensitive patients was analysed by immunofluorescence with confocal microscopy. Plasma biomarkers (P-selectin, VWF, PAI-1, t-PA, D-dimer, TF pathway markers, plasmin and CD34+) were measured simultaneously on peripheral blood. Lysis-resistant clots had higher levels of fibrin (p=0.02), P-selectin (p=0.03) and VWF (p=0.01) than lysis-sensitive clots. Among thrombi obtained ≤ 6 hours after onset of symptoms, those from lysis-resistant patients showed a higher content in fibrin than those from p-PCI patients (p=0.01). Plasma PAI-1 (p=0.02) and D-dimer levels were significantly higher (p=0.003) in lysis-resistant patients, whereas plasmin levels were lower (p=0.03). Multivariate analysis showed the content of fibrin and VWF within thrombus as predictors of thrombolysis resistance. In conclusion, coronary thrombi in STEMI patients resistant to fibrinolysis are characterised by higher fibrin, P-selectin and VWF content than lysis-sensitive thrombi.

Entities:  

Keywords:  Clot structure; coronary syndrome; fibrin; fibrinolytic disorders; von Willebrand factor

Mesh:

Substances:

Year:  2016        PMID: 26962963     DOI: 10.1160/TH15-12-0985

Source DB:  PubMed          Journal:  Thromb Haemost        ISSN: 0340-6245            Impact factor:   5.249


  9 in total

1.  Dissecting stroke for anti-VWF therapeutics.

Authors:  Jing-Fei Dong
Journal:  Blood       Date:  2016-05-12       Impact factor: 22.113

2.  Microfluidics contrasted to thrombelastography: perplexities in defining hypercoagulability.

Authors:  Peter J Lawson; Hunter B Moore; Ernest E Moore; Mark E Gerich; Gregory R Stettler; Anirban Banerjee; Richard D Schulick; Trevor L Nydam
Journal:  J Surg Res       Date:  2018-06-08       Impact factor: 2.192

3.  The development and characterization of a long acting anti-thrombotic von Willebrand factor (VWF) aptamer.

Authors:  Shuhao Zhu; James C Gilbert; Paul Hatala; Warren Harvey; Zicai Liang; Shan Gao; Daiwu Kang; Bernd Jilma
Journal:  J Thromb Haemost       Date:  2020-03-05       Impact factor: 5.824

4.  Enhanced activity of an ADAMTS-13 variant (R568K/F592Y/R660K/Y661F/Y665F) against platelet agglutination in vitro and in a murine model of acute ischemic stroke.

Authors:  K South; F Denorme; I I Salles-Crawley; S F De Meyer; D A Lane
Journal:  J Thromb Haemost       Date:  2018-10-24       Impact factor: 5.824

5.  Plasminogen activator inhibitor-1 activity and long-term outcome in patients with ST-elevation myocardial infarction treated with primary percutaneous coronary intervention: a prospective cohort study.

Authors:  Marin Pavlov; Vjeran Nikolić-Heitzler; Zdravko Babić; Milan Milošević; Krešimir Kordić; Ivana Ćelap; Vesna Degoricija
Journal:  Croat Med J       Date:  2018-06-30       Impact factor: 1.351

6.  Novel Biomarkers, ST-Elevation Resolution, and Clinical Outcomes Following Primary Percutaneous Coronary Intervention.

Authors:  Jay S Shavadia; Christopher B Granger; Wendimagegn Alemayehu; Cynthia M Westerhout; Thomas J Povsic; Sean Van Diepen; Christopher Defilippi; Paul W Armstrong
Journal:  J Am Heart Assoc       Date:  2020-06-17       Impact factor: 5.501

7.  D-dimer for risk stratification and antithrombotic treatment management in acute coronary syndrome patients: asystematic review and metanalysis.

Authors:  Flavio Giuseppe Biccirè; Alessio Farcomeni; Carlo Gaudio; Pasquale Pignatelli; Gaetano Tanzilli; Daniele Pastori
Journal:  Thromb J       Date:  2021-12-18

8.  Consensus clustering of gene expression profiles in peripheral blood of acute ischemic stroke patients.

Authors:  Zhiyong Yang; Guanghui Wang; Nan Luo; Chi Kwan Tsang; Li'an Huang
Journal:  Front Neurol       Date:  2022-08-05       Impact factor: 4.086

9.  The Effects of Curcumae Longae Radix, Curcuma phaeocaulis Radix and Their Processed Products on Epo/EpoR Pathway and CD62p.

Authors:  Zhimin Chen; Wenbing Li; Liang Quan; Haiting Zhou; Yongfeng Zhao; Xi Zhang; Lin Hu; Changjiang Hu
Journal:  Front Pharmacol       Date:  2018-07-09       Impact factor: 5.810

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.